Atlas Trials

CD19 and CD22 Dual-targeted CAR-T Cells for Relapsed or Refractory B-NHL

Clinical trial NCT04303247 · UNKNOWN

Trial details

NCT number
NCT04303247
Sponsor
Xinqiao Hospital of Chongqing
Status
UNKNOWN
Phase
Early Phase 1
Study type
INTERVENTIONAL
B-cell Lymphoma RefractoryB-cell Lymphoma Recurrent
Start date
2020-05-01
Primary completion
2021-05-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.